{"id":"NCT00927069","sponsor":"Innovaderm Research Inc.","briefTitle":"Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept","officialTitle":"Open Label Study to Evaluate the Efficacy and Safety of Adalimumab in Patients With Plaque Psoriasis Who Showed an Unsatisfactory Response to Etanercept","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2008-09","completion":"2008-12","firstPosted":"2009-06-24","resultsPosted":"2010-08-24","lastUpdate":"2011-09-09"},"enrollment":85,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Adalimumab every other week","otherNames":["HUMIRA"]},{"type":"DRUG","name":"Adalimumab Every Week","otherNames":["HUMIRA"]}],"arms":[{"label":"Group A","type":"EXPERIMENTAL"},{"label":"Group B","type":"EXPERIMENTAL"},{"label":"Group A dose increase at Week 12","type":"EXPERIMENTAL"},{"label":"Group B dose increase at Week 12","type":"EXPERIMENTAL"}],"summary":"This study will provide data on additional therapeutic benefits in administering Adalimumab in patients with plaque psoriasis that showed an unsatisfactory response after at least 3 months of treatment with etanercept.","primaryOutcome":{"measure":"Number of Patients From Group B Who Achieve a Physician's Global Assessment (PGA) of Clear or Almost Clear at Week 12.","timeFrame":"12 weeks","effectByArm":[{"arm":"Group B","deltaMin":11,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":20},"locations":{"siteCount":12,"countries":["Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["Upper Respiratory Tract Infection","Common Cold","Headache","Back Pain","Sinusitis"]}}